US Stocks Movement: WuLong Pharmaceuticals surged on November 16 as ZUSDURI revenue increased by 35% and Q4 profit guidance was released
Bitget异动解读2026/11/16 16:01Wulong Pharmaceuticals November 16 Surge Analysis
Keywords: ZUSDURI revenue increases by 35%, Q4 profit guidance
1. On November 4, 2026, the third quarter financial report was released: ZUSDURI’s net product revenue reached $68 million, up 35% quarter-on-quarter; total revenue was $89 million, more than double year-on-year; net loss narrowed to $1.5 million.
2. At the November 4, 2026 earnings call, it was stated that the company expects to achieve profitability and generate positive cash flow in Q4 2026. As of September 30, it held $90.5 million in cash and $117 million in accounts receivable.
3. On November 4, 2026, it was disclosed that the FDA has accepted the UGN-103 new drug application. The PDUFA target date is June 14, 2027, and the new patent extends protection until July 2044.
4. On November 2, 2026, it was announced that the first patient was dosed in the phase 1 trial of UGN-501, a next-generation oncolytic virus therapy for non-muscle invasive bladder cancer.
(Disclaimer: This content is summarized from public information gathered by AI technology for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Claude’s usage in Microsoft 365 is less than one tenth of Copilot’s.



Nvidia DDGX B200 system will connect to the IBM Quantum Nighthawk quantum computer
